Stockscreener 앱 받기
7.18
0.00%
0.00
시간 외 거래:
7.20
0.02
+0.28%
전일 마감가:
$7.18
열려 있는:
$7.23
하루 거래량:
944.53K
Relative Volume:
0.41
시가총액:
$1.19B
수익:
$246.03M
순이익/손실:
$-32.00M
주가수익비율:
-33.79
EPS:
-0.2125
순현금흐름:
$-16.78M
1주 성능:
+5.12%
1개월 성능:
-22.21%
6개월 성능:
+50.21%
1년 성능:
+108.12%
1일 변동 폭
$7.10
$7.24
1주일 범위
$6.80
$7.24
52주 변동 폭
$3.14
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.18 | 1.19B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-12 | 재개 | H.C. Wainwright | Buy |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
What drives Xeris Biopharma Holdings Inc 2B30 stock priceDividend Stability Analysis & Stay Safe With Built-In Risk Monitoring - earlytimes.in
Xeris Biopharma Faces Weak Start with 15% Gap Down Amid Market Concerns - Markets Mojo
How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stockIndex Update & Accurate Entry/Exit Alerts - newser.com
Will Xeris Biopharma Holdings Inc. (2B30) stock hit Wall Street targetsPortfolio Value Summary & Low Drawdown Investment Ideas - newser.com
Will Xeris Biopharma Holdings Inc. stock deliver long term returns2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Detecting support and resistance levels for Xeris Biopharma Holdings Inc.2025 Year in Review & Verified Stock Trade Ideas - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsJuly 2025 Rallies & Daily Chart Pattern Signals - newser.com
Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade - Sahm
What high frequency data says about Xeris Biopharma Holdings Inc.2025 Support & Resistance & Risk Controlled Swing Alerts - newser.com
How sentiment analysis helps forecast Xeris Biopharma Holdings Inc.Trade Volume Report & Long-Term Safe Investment Ideas - newser.com
How Raised 2025 Revenue Guidance and Q3 Profitability Will Impact Xeris Biopharma (XERS) Investors - Sahm
Hecht Beth, chief legal officer, sells Xeris Biopharma (XERS) shares for $123k - Investing.com India
Officer Hecht Files To Sell 66,668 Of Xeris Biopharma Holdings Inc [XERS] - TradingView
Is Xeris Biopharma Holdings Inc. (2B30) stock supported by strong fundamentalsIPO Watch & Weekly Chart Analysis and Trade Guides - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendationsTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Is Xeris Biopharma Holdings Inc. (2B30) stock cheap vs fundamentalsJuly 2025 PreEarnings & Stepwise Entry and Exit Trade Signals - newser.com
Is a relief rally coming for Xeris Biopharma Holdings Inc. holdersStock Surge & Community Consensus Stock Picks - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock could be top winnerWeekly Stock Summary & Daily Stock Trend Reports - newser.com
Is Xeris Biopharma Holdings Inc. stock entering bullish territoryJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Applying chart zones and confluence areas to Xeris Biopharma Holdings Inc.Oil Prices & Consistent Growth Equity Picks - newser.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
Q4 2024 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma (XERS) Turns Profitable and Lifts 2025 Outlook but What Will Sustain Growth? - Sahm
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2025 Earnings Call Transcript - Insider Monkey
Xeris raises 2025 revenue guidance to $285M-$290M as RECORLEV revenue more than doubles year-over-year - MSN
Xeris Biopharma Holdings, Inc. (2B30.F) stock price, news, quote and history - Yahoo Finance Singapore
Xeris Biopharma Hits Day Low at $7.00 Amid Price Pressure - Markets Mojo
Xeris Biopharma Holdings Inc (XERS) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 - BioSpace
Assessing Xeris Biopharma (XERS) Valuation Following Strong Q3 Earnings and Raised Revenue Guidance - simplywall.st
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
1.13%
자본화:
|
볼륨(24시간):